TeamStaff, Inc. (TSTF) shares rebound slightly on news of executive leadership changes

TeamStaff, Inc. (Nasdaq: TSTF), reached 60 cents today after dipping to 54 cents at Friday’s close, after announcing this morning the appointment of Mr. John E. Kahn as Chief Financial Officer. TeamStaff, a leading logistics and healthcare services provider to the Federal Government and Department of Defense, conducted the executive search with the assistance of DHR International.

Bringing over 25 years of financial experience to the corporation, Mr. Kahn will be responsible for all elements of accounting and finance for the organization. Leading up to his appointment at TeamStaff, Mr. Kahn served as CFO of Financial Asset Management Systems, an American Capital backed government and business services group. Furthermore, Kahn has over a decade of experience as a CFO and extensive experience in publicly traded organizations. Mr. Kahn began his career with what is now BAE Systems, before joining a large public accounting firm.

Zach Parker, Chief Executive Officer of TeamStaff commented on Kahn’s appointment, stating, “We are delighted to welcome John to TeamStaff. With his appointment, we are in an even stronger position to deliver on our objective of becoming a nationally recognized leader with the Federal Government and DoD in the logistics and healthcare fields.”

Mr. Kahn holds leadership roles with several professional associations including Financial Executives International (FEI), the Association of Chartered Accountants in the United States (ACAUS) and the Association for Corporate Growth (ACG).

“John not only has a proven track record in corporate finance, growing businesses and managing complex capital structures, but he also has a depth of financial and operational experience in the government services and defense industries that will be invaluable in helping TeamStaff achieve its business objectives,” Parker concluded.

Sinobiopharma (SNBP) reports strong fiscal year 2010 financials

Share prices for Sinobiopharma, Inc. (OTCBB: SNBP) are up 15.4 percent from last week, to 30 cents a share, after the company announced promising financial results, with solid increases in revenues and profits driven by higher sales of their flagship product, KuTai, a muscle relaxant. The Company is pleased to report 2010 revenue rose 101 percent to $7.7 million, and net income increased approximately $5.1 million year-over-year to $2.9 million, or three cents per diluted share.

Sinobiopharma, a fully integrated and innovative specialty pharmaceutical company engaged the development and distribution of biopharmaceutical products in China, also reported that their gross margin increased 142 percent year-over-year to approximately $6.2 million, or 80 percent of sales from $2.5 million in contrast to $2.5 million, or 66 percent during the same period of 2009. Additionally, net worth increased from $776,831 at May 31, 2009 to $9,752,831 at May 31, 2010. Total assets increased by $5,996,519, from $5,956,443 at May 31, 2009 to $11,952,962 at May 31, 2010.

Dr. Lequn Lee Huang, Sinobiopharma’s Chairman and CEO, commented on the fiscal year 2010 results, “This has been a great year for Sinobiopharma. The market has demonstrated a strong need for our flagship product – KuTai – and the sales increases from this product are expected to continue for the next two years. The cash flow generated organically is expected to fully support ongoing operations.”

Sinobiopharma’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. The company is known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd., Sinobiopharma’s wholly-owned subsidiary in China, one of the world’s fastest growing pharmaceutical markets.

Cord Blood America (CBAI) volume skyrockets on acquisition news

Cord Blood America, Inc. (OTCBB: CBAI) experienced explosive activity Monday, trading nearly 40 million shares after announcing this morning that the Company has acquired a 50.1 percent controlling interest in Biocordcell Argentina S.A. (BioCells, Inc.), one of South America’s largest stem cell companies. Cord  Blood America primarily focuses on the preservation of umbilical cord blood stem cell  in order to bring the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally.

Commanding a major part of the market in South America, BioCells is headquartered in Argentina with operations in Peru, Colombia, Bolivia, Panama and Puerto Rico, with recent expansion into Uruguay and Paraguay.  Purchase price for the profitable stem cell storage company, the second largest in Argentina, depends on achieving earn out targets for net profit over the next two years.

BioCells, Inc. reported 2009 annual revenues of $1.2 million (US), and operates twelve locations throughout Argentina, serving the nation of 40 million people that historically saves umbilical cord blood stem cells at a rate even higher than in the United States.

Co-founder and Chief Executive Officer of Cord Blood America, Matthew Schissler commented, “We expect revenues from BioCells to be approximately $1.7 million in 2010, with a profit of $150,000 (U.S.) before taxes. With this acquisition in South America, we now own a state-of-the-art large laboratory in Las Vegas, Nevada, a stem cell company in Germany with expansion plans throughout Europe, and we are partners in what could be the world’s largest stem cell storage facility in China.  We are quite proud of the accomplishments of Cord Blood America and we have no intention of slowing our aggressive growth strategy.”

Schissler concluded, “This is an historic day for Cord Blood America, our loyal investors and stakeholders.  We will not rest until we meet our goal of becoming the world’s premier stem cell storage company.”

Mass Megawatts (MMGW) reports fiscal quarter net losses

Mass Megawatts Wind Power, Inc. (OTCBB: MMGW) announced today disappointing quarterly results for the first fiscal quarter ending July 31, 2010. These results include a net loss of $150,399 or two cents per share, compared with a net loss of two cents per share or $131,558 for the same period last year.

Mass Megawatts, based in Worcester, Massachusetts, specializes in the development of a revolutionary wind power technology, and in recent news, the Company reported that it had improved its product design in order to reduce the cost of wind power using modified augmenters.

Although the quarterly statements report a loss, the Company, with less than ten million shares issued and outstanding, continues to have an improved financial position in the recent quarter. Without the burden of cash and debt issues, Mass Megawatts has the ability to complete the goals related to product development and the preparation for mass production of their MAT wind turbines.

Mass Megawatts has had a descending and turbulent past six months, sliding 60 percent from over 80 cents in March to a low of 32 cents today, with daily shares prices ranging as much as 20 cents.